The startup develops a biotechnology platform that integrates U.S. biotechnology with Chinese research and clinical resources to provide cost-effective cellular therapies using CAR-NK and dendritic cell (DC) technologies. This approach aims to enhance human immunity against cancer, enabling patients to utilize their immune systems more effectively in the fight against the disease.
Funding
Funding not disclosed
Founders
Product
Problem
Cancer patients often face challenges in effectively utilizing their immune systems to combat the disease. Traditional cancer treatments can be expensive and may not always harness the full potential of the body's natural defenses.
Solution
This startup is developing cellular therapies using CAR-NK (Chimeric Antigen Receptor-Natural Killer) and dendritic cell (DC) technologies to enhance the body's immune response against cancer. By integrating biotechnology with research and clinical resources, the company aims to provide cost-effective and accessible treatments. The CAR-NK cells are engineered to target and destroy cancer cells, while the dendritic cells are designed to stimulate and educate the immune system to recognize and attack tumors. This approach seeks to empower patients by enabling their immune systems to more effectively fight cancer.
Target Audience
The primary target audience includes cancer patients seeking innovative and accessible treatment options, as well as oncologists and medical centers looking to expand their therapeutic offerings.
Features
- CAR-NK cell therapy platform for targeted destruction of cancer cells.
- Dendritic cell (DC) therapy platform to stimulate and educate the immune system.
- Integration of research and clinical resources for efficient development and testing.
- Focus on cost-effectiveness to improve accessibility for patients.